ArticleResearch in pharmaceutical sciences2019
Article in Research in pharmaceutical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Nano-encapsulatedRSC advances · 2026Article
- Comparative Kinetic Modeling and Mathematical Analysis of Monoterpene Release from Nanocarrier Systems.AAPS PharmSciTech · 2026Article
- D-Limonene Exhibits Antiproliferative Activity Against Human Colorectal Adenocarcinoma (Caco-2) Cells via Regulation of Inflammatory and Apoptotic Pathways.Current issues in molecular biology · 2025Article
- Fabrication of Chrysin-Loaded Hyaluronic Acid Decorated Niosomal Nanoparticles: Potential Anti-inflammatory and Anti-osteoclastic Effects on PBMCs of Rheumatoid Arthritis Patients.Advanced pharmaceutical bulletin · 2025Article
- From Citrus to Clinic: Limonene's Journey Through Preclinical Research, Clinical Trials, and Formulation Innovations.International journal of nanomedicine · 2025Review
- Niosome as a Drug Delivery Carrier for Sorafenib: Preparation, Investigation of Physicochemical Properties, andAdvanced pharmaceutical bulletin · 2024Article
- Niosome-loaded Tet-Amp against S. aureus, K. pneumoniae, and P. aeruginosa.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Co-delivery of artemisinin and metformin via PEGylated niosomal nanoparticles: potential anti-cancer effect in treatment of lung cancer cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Molecular interactions between metformin and D-limonene inhibit proliferation and promote apoptosis in breast and liver cancer cells.BMC complementary medicine and therapies · 2024Article
- Fabrication, optimization, and characterization of pH-responsive PEGylated nanoniosomes containing gingerol for enhanced treatment of breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Current advances in niosomes applications for drug delivery and cancer treatment.Materials today. Bio · 2023Review
- Drug delivery methods based on nanotechnology for the treatment of eye diseases.Annals of medicine and surgery (2012) · 2023Review
- Oral nicotine pouches with an aftertaste? Part 2: in vitro toxicity in human gingival fibroblasts.Archives of toxicology · 2023Article
- Citrus By-Products as a Valuable Source of Biologically Active Compounds with Promising Pharmaceutical, Biological and Biomedical Potential.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects.Pharmaceutics · 2023Article
- Design and optimization various formulations of PEGylated niosomal nanoparticles loaded with phytochemical agents: potential anti-cancer effects against human lung cancer cells.Pharmacological reports : PR · 2023Article
- Lime and orange essential oils and d-limonene as a potential COVID-19 inhibitor: Computational,Food bioscience · 2023Article
- Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform.Molecules (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The low solubility of the plant-extracted agent like D-limonene in cancer therapy is a critical problem. In this study, we prepared D-limonene-loaded niosomes (D-limonene/Nio) for cancer therapy through
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.